OTC · Health care

Nymox Pharmaceutical Corp (NYMXF)

It posted a net loss of $4.5M. In fiscal 2024 capital spending exceeded operating cash flow by $2.6M. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on September 16, 2026.

Watch NYMXF in 60 seconds

Price

$0.10

0.00% on the day · September 25, 2026

52-week range $0.00 to $0.20

What Nymox Pharmaceutical Corp does

Nymox Pharmaceutical Corp is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on OTC under the ticker NYMXF.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2024	n/a	-$4.3M	-$4.5M	-$0.05	-$2.6M
2023	$0	-$8.4M	-$8.8M	-$0.10	-$4.1M
2022	$0	-$6.7M	-$6.6M	-$0.07	-$5.2M
2021	$0	-$12.5M	-$12.5M	-$0.15	-$9.8M
2020	$5K	-$11.7M	-$11.7M	-$0.16	-$10.1M
2019	$116K	-$13.3M	-$13.2M	-$0.19	-$7.4M

Full financial statements: income, balance sheet and cash flow

Next report expected around September 22, 2027.

Estimated from its filing rhythm: about 373 days after its last report of September 14, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Nymox Pharmaceutical Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 16, 2026
Annual report (foreign issuer, amended) 20-F/A · period to December 31, 2025
September 14, 2026
Annual report (foreign issuer) 20-F · period to December 31, 2025
August 31, 2026
Foreign issuer update 6-K
August 7, 2026
Foreign issuer update 6-K
June 3, 2026
Foreign issuer update 6-K
March 27, 2026
Foreign issuer update 6-K
November 7, 2025
Foreign issuer update 6-K
October 22, 2025
Foreign issuer update 6-K
October 22, 2025
Foreign issuer update 6-K
September 23, 2025
Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 26, 2023. Insider transactions on SEC

All filings on SEC EDGAR

Questions about NYMXF

What does Nymox Pharmaceutical Corp do?

Nymox Pharmaceutical Corp is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on OTC under the ticker NYMXF.

Is Nymox Pharmaceutical Corp profitable?

No. In fiscal 2024 it reported a net loss of $4.5M.

When did Nymox Pharmaceutical Corp last report?

Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on September 16, 2026. It covers the period to December 31, 2025.

Similar companies

IDXX

Idexx Laboratories Inc

QDEL

QuidelOrtho Corp

LNTH

Lantheus Holdings, Inc.

Intellia Therapeutics, Inc.

Compare NYMXF with

Compare NYMXF with any company

Follow NYMXF

Get an email when Nymox Pharmaceutical Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow NYMXF: get an email when it files

Where the numbers come from

Financial figures are the values Nymox Pharmaceutical Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.